In light of the significant drop in Regeneron’s stock price, a natural question emerges: is REGN now a viable buying opportunity?

What Happened? Shares of biotech company Regeneron (NASDAQ:REGN) fell 19% in the afternoon session after the company announced mixed results from its Phase 3 trials for itepekimab, an experimental ...

Revenue declined 4% from the prior year, as Regeneron struggled to offset the double-digit decline in net product ... down 6.8% from previous close. The stock market overreacts to news, and ...

Regeneron Pharmaceuticals' (NASDAQ:REGN) stock is trading in the red premarket ... COVID‑19 antibody therapy REGEN-COV saw a decline of -3.52% Y/Y to $613.2M in global sales, which consisted ...

Shares of Regeneron Pharmaceuticals, Inc. REGN have dropped 35.6% in the past six months compared with the industry’s decline of 12.3%. The stock has underperformed the sector and the S&P 500 ...

Regeneron is bearing the brunt of investors of late as Eylea’s sales witness a rapid decline. Earlier, the stock took a hit after an unfavorable ruling in its lawsuit against Amgen in the United ...

Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) stock has experienced a notable downturn, touching a 52-week low of $666.With a market capitalization of $71.55 billion and a P/E ratio of 15.6x, this ...

Revenue declined 4% from the prior year, as Regeneron struggled to offset the double-digit decline in net product sales, including a 29% plunge in legacy EYLEA, despite a 54% jump in EYLEA HD. Overall ...

One stock in particular has grabbed my attention during this selloff. Regeneron's decline has been epic, and now may be the time to buy. Regeneron's stock, REGN, was taken to the woodshed.